Abstract:Anaplastic lymphoma kinase rearranged (ALK+) non–small-cell lung cancer demonstrates remarkable sensitivity to crizotinib.1Camidge DR Bang YJ Kwak EL et al.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol. 2012; 13: 1011-1019Abstract Full Text Full Text PDF PubMed Scopus (1064) Google Scholar Although other methods exist, the dominant method for determining ALK positivity uses the Abbott (Abbott Molecular, Des Plaines, IL) ALK break-apart fluorescent in situ hybridization (FISH) assay.2Weickhardt AJ Aisner DL Franklin WA Varella-Garcia M Doebele RC Camidge DR Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.Cancer. 2013; 119: 1467-1477Crossref PubMed Scopus (66) Google Scholar The assay has clearly defined positivity criteria but borderline or atypical negative cases occur. Here we describe a case with an atypical negative FISH result that was later confirmed as ALK+ by both immunohistochemistry (IHC) and reverse transcription polymerase chain reaction (RT-PCR)and responded well to crizotinib. A 44-year-old Chinese man with a 7 pack-year smoking history was referred to Shanghai Pulmonary Hospital in February 2013 for a left upper lobe lung mass with multiple bilateral intrapulmonary metastases, left pleural effusion, and 2R/4R/10L/11L lymphadenopathy. Pleural fluid cytology revealed adenocarcinoma and Scorpion Amplification Refractory Mutation system (AmoyDx Co., Xiamen, China). showed no detectable epidermal growth factor receptor mutation. He commenced chemotherapy with gemcitabine and cisplatin. However, after a single cycle, his symptoms worsened and imaging confirmed progressive disease. A second opinion was requested from the University of Colorado and a computed tomography–guided biopsy of the left upper lobe lesion was performed to permit additional molecular testing. In the interim, the patient commenced pemetrexed and nedaplatin. Unfortunately, after two cycles his shortness of breath worsened, with evidence of further progression on his scans (Fig. 1A). Molecular testing on his repeat biopsy specimen revealed no mutations by SNaPshot multiplex PCR testing (Life Technologies, Carlsbad, CA). However, although technically negative, the ALK break-apart FISH test showed an atypical negative pattern. Specifically, 68% of cells demonstrated single copies of the 5′ ALK signal and numerous cells with doublets of the 5′ ALK signal combined with one 3′ ALK signal (Fig. 2A). Subsequently, confirmatory diagnostic assays demonstrated ALK protein expression by IHC using the D5F3 antibody (Cell Signaling Technology Inc., Danvers, MA; H score = 150; Fig. 2B) and the presence of an echinoderm microtubule-associated protein-like 4 (EML4)-ALK transcript (E13;A20) by RT-PCR (Fig. 2C). The patient then received crizotinib (250 mg twice daily) as third-line therapy in May 2013 with an impressive symptomatic improvement and CT response after 1 month of therapy (Fig. 1B). He remains on treatment with crizotinib with no evidence of progression as of September 2013. Isolated 5′ ALK signals have previously been reported, although, because the 5′ probe is not located in the kinase region of ALK, these are usually considered ALK negative by FISH.3Yoshida A Tsuta K Nitta H et al.Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas.J Thorac Oncol. 2011; 6: 1677-1686Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar,4Camidge DR Kono SA Flacco A et al.Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.Clin Cancer Res. 2010; 16: 5581-5590Crossref PubMed Scopus (297) Google Scholar Our patient showed multiple single copies of the 5′ ALK signal plus additional 5′ doublets combined with 3′ signals, suggesting the possibility of a complex rearrangement. ALK positivity was confirmed by both IHC and RT-PCR and the patient responded well to crizotinib. A complex rearrangement generating a different atypical negative FISH pattern (3′ doublets fused with 5′ signals) that also harbored a functional ALK fusion was recently described.5Peled N Palmer G Hirsch FR et al.Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.J Thorac Oncol. 2012; 7: e14-e16Abstract Full Text Full Text PDF PubMed Scopus (114) Google Scholar When FISH is the initial diagnostic assay, consideration should be given to formally defining an atypical negative ALK FISH category for additional interrogation with alternative confirmatory assays.2Weickhardt AJ Aisner DL Franklin WA Varella-Garcia M Doebele RC Camidge DR Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.Cancer. 2013; 119: 1467-1477Crossref PubMed Scopus (66) Google Scholar

Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS

Accurate and Economical Detection of ALK Positive Lung Adenocarcinoma with Semiquantitative Immunohistochemical Screening

IHC versus FISH versus NGS to detect ALK gene rearrangement in NSCLC: all questions answered?

A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma

The Molecular Detection and Clinical Significance of ALK Rearrangement in Selected Advanced Non-Small Cell Lung Cancer: ALK Expression Provides Insights into ALK Targeted Therapy.

Atypical Negative Alk Break-Apart Fish Harboring A Crizotinib-Responsive Alk Rearrangement in Non-Small-Cell Lung Cancer

Concordance of Immunohistochemistry and Fluorescent in Situ Hybridization for Anaplastic Lymphoma Kinase (alk) Rearrangement in Non-Small Cell Lung Cancer: Results from A Multicenter Study in China

Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment.

Comparison of ALK Status Between Primary and Corresponding Lymph Node Metastatic Tumors in Lung Cancer Patients

Assessment of Alk Rearrangement in Advanced Non-Small Cell Lung Cancer Using Fluorescence in Situ Hybridization & Immunohistochemistry

Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer

Comparison of ALK Detection by FISH, IHC and NGS to Predict Benefit from Crizotinib in Advanced Non-Small-cell Lung Cancer.

Screening of Nsclc Samples from Chinese Lung Cancer Patients for Activating Rearrangements of the Alk, Ret, and Ros1 Genes.

A Study of ALK-positive Pulmonary Squamous-Cell Carcinoma: from Diagnostic Methodologies to Clinical Efficacy.

A comparative analysis of immunohistochemistry and fluorescent in situ hybridization assay to detect anaplastic lymphoma kinase status in lung adenocarcinoma cases: A search for a testing algorithm

Development of a novel ALK rearrangement screening test for non-small cell lung cancers

Shifting from Immunohistochemistry to Screen for ALK Rearrangements: Real-World Experience in a Large Single-Center Cohort of Patients with Non-Small-Cell Lung Cancer

Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC

Evaluation Of Alk Rearrangement In Chinese Non-Small Cell Lung Cancer Using Fish, Immunohistochemistry, And Real-Time Quantitative Rt- Pcr On Paraffin-Embedded Tissues

Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma